MFMaryam Fouladi

Maryam Fouladi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maryam Fouladi has a total of 149 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • SPROUT Guidelines for Molecular Profiling for Children with Solid Tumors: A Consensus Recommendation from the American Association for Cancer Research

    by Catherine Gestrich, Larissa V. Furtado, Jaclyn Biegel, Maryam Fouladi, Andrew L. Kung, Theodore W. Laetsch, Sarah Leary, Marilyn M. Li, Elaine Mardis, David Malkin, et al.

    Purpose: Molecular diagnostics are standard of care for most adults with solid malignancies, but implementation in pediatric solid tumors remains inconsistent. The SPROUT (Somatic Profiling for Pediatric Cancer Refining our Understanding and Treatment) Molecular Guidelines Working Group was convened to develop molecular testing guidelines for pediatric solid tumors. Experimental Design: A structured literature review was performed using Covidence to identify relevant clinical studies evaluating molecular diagnostics in pediatric solid tumors. The literature and collective clinical experience of the multidisciplinary working group were used to develop consensus recommendations for molecular profiling at diagnosis and at relapse or recurrence. Results: Of 361 manuscripts screened, 41 studies were included for data extraction. Based on the available evidence and expert consensus, recommendations were developed for the use and timing of DNA and RNA next-generation sequencing and methylation profiling across pediatric solid tumors. Conclusions: The SPROUT Molecular Guidelines provide a framework for standardized implementation of molecular diagnostics in pediatric solid tumors. Broad adoption of these recommendations may improve diagnostic precision, reduce variability in molecular testing, and increase opportunities for biomarker-directed therapy and clinical trial enrollment for children with cancer.

  • Open Access

    Longitudinal caregiver- and patient-reported health-related outcomes of pediatric patients with high-grade gliomas enrolled on CONNECT1701 and CONNECT1702

    by Mariah Wright-Nadkarni, Emily L Moscato, Joseph R Stanek, Megan R Schaefer, Cynthia A Gerhardt, David M Ashley, Patricia A Baxter, Susan N Chi, Kathleen Dorris, Michael J Fisher, et al.

    Introduction: Children with high-grade glioma (HGG), including diffuse intrinsic pontine glioma (DIPG), experience psychosocial and physical sequelae, negatively impacting health-related quality of life (HRQoL). Limited data exists on psychosocial functioning in this population. We longitudinally assessed caregiver-proxy and patient-reported HRQoL and functional outcomes of children with HGG on early-phase trials involving upfront radiotherapy (RT) and oral agents. Methods: PROMIS short forms were administered to patients ≥8 years-old and caregivers of patients aged 5-17 years-old. T-scores (M = 50, SD = 10) were calculated relative to the general population. Linear mixed modeling compared scores at pre-RT, post-RT, 1-month pre-progression, and end of therapy (EOT). Results: Twenty-nine patients and 43 caregivers participated. Patients and caregiver-proxies reported comparable emotional distress, physical function, and family relationships to norms. There were no significant differences for depressive symptoms, peer relationships, or family relationships for caregiver-proxies or patients across timepoints. Caregivers-proxies reported higher anxiety pre-RT compared to post-RT and pre-progression. Fatigue, pain interference, mobility, and upper extremity function were reported as mild- to moderately worse compared to the general population, particularly pre-RT and EOT. Caregivers reported higher physical symptoms than patients, but most caregiver-proxy and patient-reported scores were similar across timepoints and domains. Conclusions: Children with HGG and their caregivers reported comparable emotional functioning and relationship quality to the general population. Physical functioning was reported as worse by caregivers pre-RT and at EOT. Caregivers appeared to overestimate psychological and physical distress compared to patient-reports. Findings may reflect resilience of this population when facing adversity, while highlighting the benefit of psychosocial supports and well-tolerated therapy on HRQoL.

  • Response to “Reporting of outcomes of young children with embryonal CNS tumors after radiotherapy-avoiding strategies: Comments on ACNS0334”

    by Sarah E S Leary, Guolian Kang, Paul D Aridgides, Jeffrey Gossett, Claire Mazewski, Maryam Fouladi

    Sarah E S Leary, Guolian Kang, Paul D Aridgides, Jeffrey Gossett, Claire Mazewski, Maryam Fouladi; Response to “Reporting of outcomes of young children wit

  • Phase 3 randomized trial of postirradiation chemotherapy in patients with newly diagnosed ependymoma: A report from the Children’s Oncology Group

    by Amy A Smith, Arzu Onar-Thomas, Shelly Lensing, James Dalton, Jeffrey Bennett, Ruth G Tatevossian, Kelsey Bertrand, Holly Lindsay, Uri Tabori, Emily Owens-Pickle, et al.

    Background: The utility of chemotherapy for childhood ependymoma is uncertain without a prior randomized trial. Methods: ACNS0831, a multicenter phase 3 randomized study conducted through the Children’s Oncology Group (COG), included patients 1-21 years with newly diagnosed intracranial ependymoma. Patients with complete/near-total resections (GTR/NTR) or complete response (CR) to induction therapy were randomized to radiation (RT) alone or RT followed by chemotherapy (RT-CHEMO). Primary outcomes were event-free survival (EFS) and overall survival (OS). Due to anticipated noncompliance with chemotherapy, an “as treated” analysis was planned. Patients with subtotal resection (STR) were non-randomly assigned to RT-CHEMO. Grade 2 supratentorial tumors with GTR or CR to induction therapy were observed. Results: Of 449 eligible patients, 325 with GTR/NTR or CR were randomized. Five-year EFS was 63.7% (95% CI: 55.1%-71.1%) for RT only (n = 161) versus 69.2% (60.8%-76.3%) for RT-CHEMO (n = 164) (1-sided log-rank P = .299, HR = 0.866). Five-year OS was 86.9% (79.8%-91.6%) for RT only versus 88.3% (81.8%-92.6%) for RT-CHEMO (1-sided log-rank P-value = .172, HR = 0.757). The “as treated” and “as randomized” analysis results were similar. Sixty-three subjects with STR were assigned to RT-CHEMO; 5-year EFS was 33.6% (22.1%-45.5%) and OS 74.0% (60.5%-83.5%). Supratentorial grade 2 tumors with GTR or CR were observed with a 5-year EFS of 66.9% (49.0%-79.7%) and OS of 100%. Molecular classification was provided for 94% (n = 422) of all subjects. Conclusions: Primary analysis showed no benefit for maintenance chemotherapy. Further follow-up is important to assess its effect on late relapses. This is the largest cohort of molecularly classified ependymomas treated on a Phase 3 randomized trial.


  • Open Access

    Outcomes following radiotherapy for atypical teratoid/rhabdoid tumor in combination with surgery and intensive chemotherapy: A report from Children’s Oncology Group study ACNS0333

    by Paul Aridgides, Anita Mahajan, Thomas E Merchant, Mark Krailo, Allen Buxton, Jared Deck, Douglas Strother, Annie Huang, Jaclyn A Biegel, Ben Ho, et al.

    Background: Children’s Oncology Group ACNS0333 treated atypical teratoid/rhabdoid tumor (ATRT) with surgery, chemotherapy (induction and consolidation) and radiation therapy (RT). M0 had focal RT and M+ had physician-selected focal RT or craniospinal (CSI). Methods: Forty patients (29 M0, 11 M+) received RT. Pre-RT chemotherapy response was complete, partial, or stable disease. RT timing (age/stage-based) was pre-consolidation (RT-first) or post-consolidation (consolidation-first). Event-free survival (RT-EFS), overall survival (RT-OS), and cumulative incidence of local relapse (CILR) or distant relapse (RT-CIDR) were calculated. Analyses included log-rank tests and relative hazard rates with 95% confidence intervals to estimate proportional hazards regression. Results: Four-year RT-EFS was 56.8% and 4-year RT-OS was 58.8% focal RT: 34 patients, CSI: 6 patients). A trend for superior RT-EFS for M+ compared to M0 (P = .0625, RHR 0.26; 95% CI 0.06-1.18) was shown. RT-EFS was improved for consolidation-first compared to RT-first timing (P = .037, RHR 0.43; 95% CI 0.13-1.37). Pre-RT chemotherapy response was associated with improved RT-EFS (P = .031) and RT-OS (P = .0069). Four-year RT-CILR was 7.84%; no differences in RT-CILR were shown for higher primary RT dose (≥5400 cGy, P = .38) or gross total resection (P = .80). 4-year RT-CIDR was 27.8% for M0 and 9.1% for M+ patients (P = .22). M+ had CSI (n = 6) or focal RT (n = 5). Fatal necrosis potentially-attributable to RT occurred in 3 RT-first patients (occuring either 1.6, 4.6, or 16.2 months post-treatment). Conclusions: RT with intensive systemic therapy showed promising survival outcomes and effective primary disease control in ATRT. Sequencing RT prior to myeloblative chemotherapy, rather than post-consolidation, may be associated with increased risk of fatal radionecrosis.


  • Open Access

    Preclinical assessment of checkpoint blockade combined with DNA methyltransferase inhibition in high-risk pediatric brain tumors reveals limited therapeutic synergy

    by Deepak Kumar Mishra, Shelli M Morris, Dean Popovski, Emily J Girard, Andrew Bondoc, Shiva Senthil Kumar, Augusto Faria Andrade, Xiaoting Zhu, Fupan Yao, Mi-Youn Brusniak, et al.

    BackgroundDespite intensive therapies, outcomes for high-risk pediatric brain tumors (PBTs) remain dismal, prompting the search for novel treatments. DNA methyltransferase inhibitors (DNMTi) have been shown to prime tumors to improve response to checkpoint inhibition. The aim of this study was to investigate the potential of decitabine (DAC), in combination with a PD-1 inhibitor, to improve survival in pediatric high-risk brain tumor models. Methods: Analysis of human PBT datasets was performed to determine gene expression levels of immune cell markers. Tumor response to DAC, with or without a PD-1 inhibitor, was tested in murine models representing H3-wildtype diffuse intrinsic pontine glioma (DIPG), H3K27-mutant diffuse midline glioma (DMG), atypical teratoid rhabdoid tumor (ATRT), and medulloblastoma (MB). CyTOF analysis of allograft tumors was performed to characterize changes within the tumor microenvironment. Results: Analysis of PBT subtypes revealed heterogeneous expression of immune cell markers, checkpoint receptors, and MHC molecules. DAC treatment decreased DNA methylation and increased neoantigen expression in human and mouse tumor cells. DAC treatment resulted in prolonged survival in syngeneic mouse models of DIPG and ATRT but not DMG and MB models. However, no added survival benefit was observed when combined with a PD-1 inhibitor. CyTOF analysis of mouse tumors revealed changes in local immune cell infiltration. Conclusions: DAC alone or in combination with a checkpoint inhibitor can alter the immune microenvironment in mouse tumor models. Changes were observed in H3-wildtype DIPG and ATRT models, suggesting that certain tumor subtypes may respond to immune priming with DNMTi.


  • Open Access

    An integrated analysis of three medulloblastoma clinical trials refines risk-stratification approaches for reducing toxicity and improving survival

    by Kyle S Smith, Sandeep K Dhanda, Catherine A Billups, Edgar Sioson, Congyu Lu, Airen Zaldivar Peraza, Karishma Gangwani, Yimei Li, Qian Li, Tong Lin, et al.

    Background: The identification of clinical and molecular heterogeneity in medulloblastoma has produced risk-stratified therapy, but establishing the most effective yet least toxic regimens has remained elusive owing to numerous treatment options. To improve risk-stratification, we performed an integrated analysis from three clinical trials. Methods: Medulloblastoma patients from ACNS0331/NCT00085735, ACNS0332/NCT00392327, and SJMB03/NCT00085202 were included if they had methylation profiling. Molecular groups [WNT, SHH, Group 3 (G3), and Group 4 (G4)], subgroups, and copy number variations were procured from methylation profiles and mutations from next-generation sequencing. Data was assembled into an interactive portal to capture patient characteristics. Cross-trial comparisons, univariable, and multivariable analyses were conducted and used to derive a risk-stratification schema. Results: Eight hundred ninety-eight patients (WNT = 131, SHH = 151, G3 = 220, G4 = 396) were included. Progression-free-survival (PFS) distributions among analogous cross-trial cohorts were not different, demonstrating no survival advantage of any one therapy over another. The addition of carboplatin to high-dose craniospinal irradiation (HDCSI) containing regimen was selectively superior in PFS in G3/G4 subgroup 3 (P = 0.048) and G3/G4 subgroup 2 (P = 0.035) to HDCSI regimens without carboplatin. Nine actionable risk-stratified groups were identified consisting of 2 WNT groups (low, high-risk), 3 SHH groups (low-, average-, very-high-risk), and 4 G3/G4 groups (low-, average-, high-, and very-high-risk). Conclusions: Our integrated cross-trial analysis suggests toxicity can be reduced by eliminating disproportionate differences in therapy in favor of a more uniform treatment backbone. Moreover, we propose and model a risk-classification system that identifies the most appropriate cohorts on which to trial significant dose reductions in craniospinal irradiation or select treatment intensifications.


  • Childhood cancer data initiative: expanded access to tumor molecular profiling for children, adolescents, and young adults

    by Joseph Flores-Toro, Subhashini Jagu, Malcolm Smith, John Shern, Douglas S Hawkins, Elaine R Mardis, Erin Rudzinski, Todd A Alonzo, Thalia Beeles, Nilsa Ramirez, et al.

    The Molecular Characterization Initiative (MCI), a key effort of the National Cancer Institute’s Childhood Cancer Data Initiative (CCDI), was launched in 2022 in collaboration with the Children’s Oncology Group (COG) to bring comprehensive genomic and molecular profiling to children, adolescents, and young adults diagnosed with cancer. The MCI provides paired tumor and germline molecular testing, with results returned to clinicians to inform care. Deidentified data are made available to the research community through the CCDI Data Ecosystem to facilitate the discovery of new treatment strategies. This commentary outlines the MCI’s development, key accomplishments to date, and its role in laying the foundation for standardized clinical diagnostics in pediatric oncology.